{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:30:45Z","timestamp":1768901445829,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671411"],"award-info":[{"award-number":["81671411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["7162062"],"award-info":[{"award-number":["7162062"]}]},{"name":"Beijing Nova Program Interdisciplinary Cooperation Projects","award":["Z161100004916045"],"award-info":[{"award-number":["Z161100004916045"]}]},{"name":"Beijing Municipality Health Technology High-level Talent","award":["2014-2-016"],"award-info":[{"award-number":["2014-2-016"]}]},{"name":"Beijing Municipal Administration of Hospitals \u2018Ascent Plan"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.maturitas.2019.01.015","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T20:33:41Z","timestamp":1548966821000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study"],"prefix":"10.1016","volume":"123","author":[{"given":"Xiangyan","family":"Ruan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muqing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiju","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred O.","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2019.01.015_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1515\/HMBCI.2011.014","article-title":"Benefits and risks during HRT: main safety issue breast cancer","volume":"5","author":"Mueck","year":"2011","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/13697137.2018.1476483","article-title":"Progesterone, progestins and the breast in menopause treatment","volume":"21","author":"Gompel","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0020","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsbmb.2007.12.002","article-title":"Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data","volume":"109","author":"Seeger","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1034\/j.1600-0412.2003.00055.x","article-title":"Hormone replacement therapy and risk of breast cancer: the role of progestins","volume":"82","author":"Stahlberg","year":"2003","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/13697130903075352","article-title":"Risk of gynecological cancers in users of estradiol\/dydrogesterone or other HRT preparations","volume":"12","author":"Schneider","year":"2009","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/AOG.0b013e31818e8cd6","article-title":"Breast cancer risk in postmenopausal women using estradiol-progestogen therapy","volume":"113","author":"Lyytinen","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0055","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2007.13.4338","article-title":"Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer","volume":"26","author":"Fournier","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/GME.0000000000000739","article-title":"Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer","volume":"24","author":"Ruan","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/gme.0b013e31820e5ac5","article-title":"The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells","volume":"18","author":"Neubauer","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/13697130802635637","article-title":"Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells","volume":"12","author":"Neubauer","year":"2009","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0075","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/13697137.2011.648232","article-title":"Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells","volume":"15","author":"Ruan","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0080","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3109\/09513590.2012.671396","article-title":"Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells","volume":"28","author":"Ruan","year":"2012","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09513590.2012.730572","article-title":"Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells","volume":"29","author":"Schneck","year":"2013","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2013.06.013","article-title":"Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1","volume":"76","author":"Zhou","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0095","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/gme.0b013e3182755c97","article-title":"Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy","volume":"20","author":"Neubauer","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2013.800038","article-title":"Possible role of PGRMC1 in breast cancer development","volume":"16","author":"Neubauer","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0105","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/gme.0b013e3182260321","article-title":"Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women\u2019s Health Initiative trial be explained by progesterone receptor membrane component 1?","volume":"18","author":"Stanczyk","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.maturitas.2017.05.007","article-title":"The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model","volume":"102","author":"Zhao","year":"2017","journal-title":"Maturitas"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2019.01.015_bib0115","first-page":"S51","article-title":"Use of dydrogesterone in hormone replacement therapy","volume":"65","author":"Mueck","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/cmt.6.3.221.227","article-title":"Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition","volume":"6","author":"Mueck","year":"2003","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0125","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr2889","article-title":"Choosing the right cell line for breast cancer research","volume":"13","author":"Holliday","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0135","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bbrc.2017.03.114","article-title":"The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer","volume":"486","author":"Yu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ygcen.2011.11.014","article-title":"Methods for long-term 17beta-estradiol administration to mice","volume":"175","author":"Ingberg","year":"2012","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0145","first-page":"6","article-title":"Food and drug administration, center for drug evaluation and research (CDER), guidance for industry","author":"U.S. Department of Health and Human Services","year":"2019","journal-title":"Pharmacol. Toxicol. J"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jsbmb.2013.08.011","article-title":"Genomic and non-genomic actions of progestogens in the breast","volume":"142","author":"Mueck","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.maturitas.2019.01.015_bib0155","doi-asserted-by":"crossref","first-page":"72480","DOI":"10.18632\/oncotarget.19819","article-title":"Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells","volume":"8","author":"Willibald","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.maturitas.2019.01.015_bib0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.maturitas.2018.06.004","article-title":"Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth","volume":"114","author":"Gu","year":"2018","journal-title":"Maturitas"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218307412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218307412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:13:21Z","timestamp":1759914801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512218307412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":32,"alternative-id":["S0378512218307412"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2019.01.015","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2019.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}